CRIXIVAN

This brand name is authorized in Austria, Cyprus, Estonia, Lithuania, Poland, Singapore, United States, South Africa

Active ingredients

The drug CRIXIVAN contains one active pharmaceutical ingredient (API):

1 Indinavir UNII 771H53976Q - INDINAVIR SULFATE

Indinavir inhibits recombinant HIV-1 and HIV-2 protease with an approximate tenfold selectivity for HIV-1 over HIV-2 proteinase. Indinavir binds reversibly to the protease active site and inhibits competitively the enzyme, thereby preventing cleavage of the viral precursor polyproteins that occurs during maturation of the newly formed viral particle. Read about Indinavir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CRIXIVAN Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AE02	Indinavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1026650, 1088276, 1088287, 1088300, 1088311, 1213254
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1010317, 1010322, 1028346, 1028350, 1028351
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100078476, 100078482
Country: SG	Health Sciences Authority	Identifier(s): 08976P
Country: US	FDA, National Drug Code	Identifier(s): 0006-0571, 0006-0573
Country: ZA	Health Products Regulatory Authority	Identifier(s): 31/20.2.8/0186